Cite
CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease.
MLA
Ibrahim, Uroosa, et al. “CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease.” Clinical Lymphoma, Myeloma & Leukemia, vol. 23, no. 10, Oct. 2023, pp. 772–78. EBSCOhost, https://doi.org/10.1016/j.clml.2023.05.007.
APA
Ibrahim, U., Bassil, C., Chavez, J. C., Khimani, F., Jain, M. D., Locke, F. L., Osman, K., & Lazaryan, A. (2023). CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease. Clinical Lymphoma, Myeloma & Leukemia, 23(10), 772–778. https://doi.org/10.1016/j.clml.2023.05.007
Chicago
Ibrahim, Uroosa, Claude Bassil, Julio C Chavez, Farhad Khimani, Michael D Jain, Frederick L Locke, Keren Osman, and Aleksandr Lazaryan. 2023. “CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease.” Clinical Lymphoma, Myeloma & Leukemia 23 (10): 772–78. doi:10.1016/j.clml.2023.05.007.